Latest Headlines
- BIOCHINA2026 – Fusion Forward: Uniting The Global Biopharma Community In Suzhou 10/20/2025
- MilliporeSigma Introduces Comprehensive AAV Express Platform For Streamlined Gene Therapy Production 10/17/2025
- 
                    TORL Biotherapeutics Secures $96M For ADC Drug Development From UCLA Lab
                        10/7/2025
                    TORL BioTherapeutics LLC (TORL), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, today announced closing of a $96 million Series C financing. Additionally, updated results from the ongoing Phase 1 study of the Company's Claudin 6 (CLDN6) targeted antibody-drug conjugate (ADC) TORL-1-23 in patients with advanced cancer will be presented in poster sessions at the 2025 European Society of Medical Oncology Congress (ESMO 2025) in Berlin, Germany. 
- 
                    RoosterBio And Secretome Therapeutics Announce Successful Completion Of Large Scale Bioreactor Production For Clinical Stage Cell Therapy Candidate STM-01
                        10/6/2025
                    RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC) today announced completion of commercial scale production of Secretome’s lead nCPC, STM-01. 
- 
                    CDMO AbbVie Begins Construction On Biologics Manufacturing Facility Expansion In Massachusetts
                        10/2/2025
                    AbbVie today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass., which serves as a center of excellence for biologics research and development and manufacturing. This expansion is part of the company's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical biologics manufacturing capabilities and capacity. 
- 
                    Federal Equipment Company Announces Exclusive Sale Of Brand-New Aseptic Processing & Sterilization Equipment
                        10/2/2025
                    Federal Equipment Company is pleased to announce the exclusive consignment of a suite of brand-new, never-used equipment designed for pharmaceutical and biotech aseptic processing. These state-of-the-art systems from leading manufacturers are now available for immediate purchase, offering buyers a unique opportunity to acquire high-performance technologies without the typical lead times of new builds. 
- 
                    Bora Pharmaceuticals Introduces High-Potency Liquid Capsule Technology In Taiwan
                        9/30/2025
                    Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, has announced the addition of liquid-filled hard capsule (LFC) production capabilities at its Zhunan, Taiwan facility. 
- Launch Of The Next Syringe Production Line 9/23/2025
- Abzena Enhances AbZelectPRO™ Cell Line Offering With New GS Knockout Platforms 9/16/2025
- 
                    Avid Bioservices Welcomes Kenneth Bilenberg As New CEO
                        9/15/2025
                    A seasoned industry executive with more than 20 years of experience, Bilenberg most recently served as Chief Operating Officer of Fujifilm Biotechnologies, leading global operations across modalities and scale. 
